Celcuity's Phase 3 VIKTORIA-1 Trial to Feature at 2025 ESMO Congress: Spotlight on Gedatolisib's Efficacy in Breast Cancer
Pivotal Data Set for European Stage—What Makes Gedatolisib Stand Out?
Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company, is making headlines as its pivotal Phase 3 VIKTORIA-1 trial data has been selected for an oral presentation at the prestigious European Society for Medical Oncology (ESMO) Congress in October 2025. This late-breaking presentation will provide the first detailed look at the efficacy and safety results for the PIK3CA wild-type cohort, placing Celcuity’s lead candidate, gedatolisib, in the spotlight for treating HR+/HER2- advanced breast cancer.
Key Presentation Details: Pivotal Data Reaches the ESMO Stage
| Presentation | Session Title | Date & Time |
|---|---|---|
| Gedatolisib + fulvestrant +/- palbociclib vs fulvestrant in HR+/HER2-/PIK3CA wild-type advanced breast cancer: First results from VIKTORIA-1 | Proffered paper session 1: Breast Cancer, metastatic | October 18, 2025, 10:15 am – 11:45 am CEST |
The upcoming ESMO session will be the first chance for clinicians and investors to get comprehensive data on the VIKTORIA-1 trial’s wild-type cohort—often a benchmark for the drug’s potential as a new therapy in advanced breast cancer.
Gedatolisib: Differentiated Mechanism Targets Multiple Cancer Pathways
What sets gedatolisib apart is its role as a potent, pan-PI3K and mTORC1/2 inhibitor. This means it can comprehensively block the PAM pathway, which is implicated in tumor growth and resistance mechanisms. Unlike other drugs that focus on one node—like PI3Ka, AKT, or mTORC1—gedatolisib targets several key molecular points simultaneously. For patients with HR+/HER2- breast cancer, especially those without PIK3CA mutations, this could offer a promising new alternative.
Robust Clinical Pipeline: More than Breast Cancer
| Trial | Therapeutic Focus | Status |
|---|---|---|
| VIKTORIA-1 | Gedatolisib + fulvestrant +/- palbociclib in HR+/HER2- ABC, PIK3CA wild-type & mutant | Wild-type cohort complete, mutant cohort enrolling |
| CELC-G-201 | Gedatolisib + darolutamide in metastatic castration resistant prostate cancer | Phase 1/2 ongoing |
| VIKTORIA-2 | Gedatolisib + CDK4/6 inhibitor and fulvestrant in HR+/HER2- ABC, first-line | Enrolling |
While the Phase 3 VIKTORIA-1 trial is the company’s immediate focus, Celcuity is building a broad clinical pipeline, including ongoing trials in metastatic prostate cancer and earlier lines of breast cancer therapy. The company’s expanding research could mean more value ahead if trial results confirm its drug’s versatility and effectiveness.
Key Takeaway: Why This Matters for Investors and Clinicians
Celcuity’s presence at ESMO with late-breaking VIKTORIA-1 data underscores its clinical and scientific progress in the competitive field of targeted cancer therapies. For clinicians, these results could shape new standards for treating HR+/HER2-/PIK3CA wild-type advanced breast cancer. For investors, October’s presentation represents a significant milestone—potentially validating the broad potential of gedatolisib and influencing the future of the company’s oncology franchise.
As anticipation builds for the late-breaking abstract on October 18, market watchers and medical professionals alike will be looking for clear signals on efficacy, safety, and commercial prospects for gedatolisib as Celcuity takes its place on the international stage.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI